keyword
MENU ▼
Read by QxMD icon Read
search

PEGylated

keyword
https://www.readbyqxmd.com/read/28218868/-diagnosis-and-treatment-of-chronic-hepatitis-b-and-d-national-consensus-guideline-in-hungary-from-15-october-2016
#1
Gábor Horváth, Zsuzsanna Gerlei, Judit Gervain, Gabriella Lengyel, Mihály Makara, Alajos Pár, László Rókusz, Ferenc Szalay, István Tornai, Klára Werling, Béla Hunyady
Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0...
February 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28218867/-screening-diagnosis-treatment-and-follow-up-of-hepatitis-c-virus-related-liver-disease-national-consensus-guideline-in-hungary-from-15-october-2016
#2
Béla Hunyady, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Gabriella Lengyel, Alajos Pár, Zoltán Péter, László Rókusz, Ferenc Schneider, Ferenc Szalay, István Tornai, Klára Werling, Mihály Makara
Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver...
February 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28218512/the-performance-of-doxorubicin-conjugated-gold-nanoparticles-regulation-of-drug-location
#3
Teng Cui, Juan-Juan Liang, Huan Chen, Dong-Dong Geng, Lei Jiao, Jian-Yong Yang, Hai Qian, Can Zhang, Ya Ding
Drug-conjugated gold nanoparticles (GNPs), which are generally constructed with many molecules of thiol-terminated polyethylene glycol (PEG)-drug decorated on their surfaces via a thiol-Au covalent bond, are promising and efficient nanoprodrugs. However, due to the exposure of the hydrophobic drug molecules on the surface of the conjugate, in vivo stability, opsonization, and subsequent inefficient therapy become the main issues of this system. To solve these problems without complicating the structures of gold conjugates, herein we propose a method to change the relative position of PEG and the drug...
February 20, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28217982/-theranostic-nanoparticles-loaded-with-imaging-probes-and-rubrocurcumin-for-a-combined-cancer-therapy-by-folate-receptor-targeting
#4
Simonetta Geninatti Crich, Diego Alberti, Morgane Frank, Nicoletta Protti, Rachele Stefania, Silva Bortolussi, Saverio Altieri, Annamaria Deagostino, Silvio Aime
The combination of different therapeutic modalities is a promising option to combat tumour recurrence. PolyLactic and Glycolic Acid nanoparticles are exploited for the simultaneous delivery of a boron-curcumin complex (RbCur) and an amphiphilic Gd complex into tumour cells with the aim of performing Boron and Gadolinium Neutron Capture Therapy (NCT) in combination with an additional curcumin anti-proliferative effect. Furthermore, the use of Gd complexes allows the MRI assessment of the amount of B and Gd internalized by tumour cells...
February 20, 2017: ChemMedChem
https://www.readbyqxmd.com/read/28217259/phase-3-trial-of-first-generation-protease-inhibitor-therapy-for-hepatitis-c-virus-human-immunodeficiency-virus-coinfection
#5
Kenneth E Sherman, Minhee Kang, Richard Sterling, Triin Umbleja, Kristen Marks, Jennifer J Kiser, Beverly Alston-Smith, Wayne Greaves, Adeel A Butt, The Actg Birth Study Team
AIM: To evaluate efficacy/safety of hepatitis C virus (HCV) protease inhibitor boceprevir with pegylated interferon (PEG-IFN) alfa and weight-based ribavirin (RBV) in a phase 3 trial. METHODS: A prospective, multicenter, phase 3, open-label, single-arm study of PEG-IFN alfa, weight-based RBV, and boceprevir, with a PEG-IFN/RBV lead-in phase was performed. The HCV/human immunodeficiency virus coinfected study population included treatment naïve (TN) and treatment experienced (TE) patients...
February 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28217253/miliary-tuberculosis-infection-during-hepatitis-c-treatment-with-sofosbuvir-and-ledipasvir-plus-ribavirin
#6
Maria Pilar Ballester-Ferré, Fernando Martínez, Natalia Garcia-Gimeno, Francisco Mora, Miguel A Serra
Chronic hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. In the last 5 years, treatment for HCV infection has experienced a marked development. In 2014, the use of ledipasvir/sofosbuvir with or without concomitant weight-based ribavirin was approved with a very significant increase in the sustained virological response. However, new side effects have been associated. We report the first case of an HCV infected patient treated for 12 wk with the combination of sofosbuvir/ledipasvir plus ribavirin who developed a miliary tuberculosis (TB) infection while on therapy...
January 28, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28215671/dual-ligand-%C3%AE-5%C3%AE-1-and-%C3%AE-6%C3%AE-4-integrin-targeting-enhances-gene-delivery-and-selectivity-to-cancer-cells
#7
Rachel M Levine, Efrosini Kokkoli
Nanoparticles functionalized with cancer-targeting ligands have shown promise but are still limited by off-tumor binding to healthy tissues that express low levels of the molecular target. Targeting two cancer biomarkers using dual-targeted heteromultivalent nanoparticles presents a possible solution to this challenge by requiring overexpression of two separate ligands for localization. In order to guide experimental design, a kinetic model was built to explore how the affinity and valency of dual-ligand liposomes affect the binding and selectivity of delivery to cells with various receptor expression...
February 16, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28215670/therapeutic-efficacy-of-combined-pegylated-liposomal-doxorubicin-and-radiofrequency-ablation-comparing-single-and-combined-therapy-in-young-and-old-mice
#8
Alexander V Andriyanov, Emma Portnoy, Erez Koren, Sara Eyal, S Nahum Goldberg, Yechezkel Barenholz
Antitumor therapy in the elderly is particularly challenging due to multiple, often chronic diseases, poly-therapy, and age-related physiological changes that affect drug efficacy and safety. Furthermore, tumors may become more aggressive and drug-resistant with advanced age, leading to poor patient prognosis. In this study, we evaluated in mice bearing medulloblastoma xenografts the effect of age on tumor progression and tumor therapy. We focused on therapeutic efficacy of two treatment modalities alone radiofrequency ablation therapy (RFA), PEGylated liposomal doxorubicin (PLD) equivalent to Doxil, and their combination...
February 16, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28210927/efficacy-and-safety-of-daclatasvir-plus-pegylated-interferon-alfa-2a-and-ribavirin-in-previously-untreated-hcv-subjects-coinfected-with-hiv-and-hcv-genotype-1-a-phase-iii-open-label-study
#9
Mark S Sulkowski, Walford J Fessel, Adriano Lazzarin, Juan Berenguer, Natalia Zakharova, Hugo Cheinquer, Pierre Côté, Douglas Dieterich, Adrian Gadano, Gail Matthews, Jean-Michel Molina, Christophe Moreno, Juan Antonio Pineda, Federico Pulido, Antonio Rivero, Jurgen Rockstroh, Dennis Hernandez, Fiona McPhee, Timothy Eley, Zhaohui Liu, Patricia Mendez, Eric Hughes, Stephanie Noviello, Peter Ackerman
BACKGROUND: Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients. METHODS: AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or ≥75 kg, 1200 mg/day), and once-weekly PegIFN 180 μg, for 24 weeks...
February 16, 2017: Hepatology International
https://www.readbyqxmd.com/read/28207300/single-nucleotide-rs760370-polymorphism-at-the-main-ribavirin-transporter-gene-detection-by-pcr-rflp-assay-compared-with-the-taqman-assay-and-its-relation-to-sustained-virological-response-in-chronic-hcv-patients-treated-with-pegylated-interferon-ribavirin
#10
Rabab Fouad, Khaled Zachariah, Marwa Khairy, Mervat Khorshied, Wafaa Ezzat, Marwa M Sheta, Ahmed Heiba
Ribavirin clearly plays a role in chronic hepatitis C treatment response. The equilibrative nucleoside transporter-1 codified by SLC29A1 gene has been associated with ribavirin uptake into hepatocytes and erythrocytes. rs760370A>G single nucleotide polymorphism (SNP) at the SLC29A1 gene may have a role in ribavirin-based regimen treatment response. Accuracy of the polymerase-chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay compared with the TaqMan assay for the detection of the SNP rs760370 at the main ribavirin transporter gene and its relation to sustained virological response in chronic hepatitis C virus (HCV) patients treated with pegylated interferon-ribavirin therapy...
February 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/28205176/determining-the-topology-of-membrane-bound-proteins-using-pegylation
#11
Vicky Howe, Andrew J Brown
Biochemical methods can help elucidate the membrane topology of hydrophobic membrane proteins where X-ray crystallography is difficult or impractical, providing important structural data. Here, we describe the method of PEGylation, which uses a cysteine-reactive molecule, maleimide polyethylene glycol (mPEG), to determine the cytosolic accessibility of introduced cysteine residues. This accessibility is visualized using Western blotting to detect a band shift that indicates cysteine labeling by mPEG. Using scanning cysteine mutagenesis, followed by PEGylation, one can map the accessibility of the introduced cysteines, hence inferring the membrane topology of the protein...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28203449/a-cost-utility-analysis-of-different-antiviral-medicine-regimens-in-patients-with-chronic-hepatitis-c-virus-genotype-1-infection
#12
Seyed Moayed Alavian, Shekoufeh Nikfar, Abbas Kebriaeezadeh, Farhad Lotfi, Ehsan Sanati, Mohsen Rezaei Hemami, Khosro Keshavarz
BACKGROUND: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted yet. OBJECTIVES: This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014...
November 2016: Iranian Red Crescent Medical Journal
https://www.readbyqxmd.com/read/28203284/novel-emerging-treatments-for-hepatitis-c-infection-a-fast-moving-pipeline
#13
REVIEW
Ara A Kardashian, Paul J Pockros
Advances in the treatment of chronic hepatitis C has been one of the pinnacles of medical science in the last 25 years. The age of direct-acting antivirals (DAAs) has led to cure rates >95% with shorter duration and low toxicity regimens, thus changing the landscape of the era of pegylated interferon and ribavirin (RBV). However, there remain some challenges with these therapies as there are multiple regimens available with a fair amount of sophistication required to administer them. Treatment continues to require knowledge of prior treatment status, viral genotype and fibrosis assessment, thus affording an opportunity for improvement in future regimens...
February 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28199034/hepatitis-b-surface-antigen-reduction-by-switching-from-long-term-nucleoside-nucleotide-analog-administration-to-pegylated-interferon
#14
Nobuharu Tamaki, Masayuki Kurosaki, Atsunori Kusakabe, Etsuro Orito, Kouji Joko, Yuji Kojima, Hiroyuki Kimura, Yasushi Uchida, Chitomi Hasebe, Yasuhiro Asahina, Namiki Izumi
Hepatitis B surface antigen (HBsAg) reduction during nucleoside/nucleotide analog (NA) therapy is slow and an alternative strategy for patients receiving ongoing NA to facilitate HBsAg reduction is required. We investigated whether switching to pegylated interferon (PEG-IFN) after long-term NA administration enhances HBsAg reduction. Forty-nine patients who switched from long-term NA to 48 weeks of PEG-IFN alfa-2a were studied. The mean duration of previous NA was 48 months (sequential group). A total of 147 patients who continued NA and matched for baseline characteristics were analyzed for comparison (NA continuation group)...
February 15, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28195491/prodrug-like-pegylated-protein-toxin-trichosanthin-for-reversal-of-chemoresistance
#15
Yingzhi Chen, Meng Zhang, Hongyue Jin, Yisi Tang, Aihua Wu, Qin Xu, Yongzhuo Huang
Multidrug resistance (MDR) is a main obstacle in cancer chemotherapy. The MDR mechanisms involve P-glycoprotein (P-gp) overexpression, abnormality of apoptosis-related protein, and altered expression of drug-targeting proteins. Therapeutic proteins are emerging as candidates for overcoming cancer MDR because of not only their large molecular size that potentially circumvents the P-gp-mediated drug efflux but also their distinctive bioactivity distinguished from small-molecular drugs. Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis...
February 14, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28193011/optimization-of-an-anti-poly-ethylene-glycol-anti-peg-cell-based-capture-system-to-quantify-peg-and-pegylated-molecules
#16
Wen-Wei Lin, Yuan-Chin Hsieh, Yi-An Cheng, Kuo-Hsiang Chuang, Chien-Chiao Huang, Chih-Hung Chuang, I-Ju Chen, Kai-Wen Cheng, Yun-Chi Lu, Ta-Chun Cheng, Yeng-Tseng Wang, Steve R Roffler, Tian-Lu Cheng
Sensitive determination of the pharmacokinetics of PEGylated molecules can accelerate the process of drug development. Here, we combined different anti-PEG Fab expressing 293T cells as capture cells (293T/3.3, 293T/6.3, and 293T/15-2b cells) with four detective anti-PEG antibodies (3.3, 6.3, 7A4, or 15-2b) to optimize an anti-PEG cell-based sandwich ELISA. Then, we quantified free PEG (mPEG2K-NH2 and mPEG5K-NH2) or PEG-conjugated small molecules (mPEG5K-biotin and mPEG5K-NIR797), proteins (PegIntron and Pegasys), and nanoparticles (Liposomal-Doxorubicin and quantum-dots)...
December 20, 2016: Analytical Chemistry
https://www.readbyqxmd.com/read/28192159/pegylation-prolongs-the-pulmonary-retention-of-an-anti-il-17a-fab-antibody-fragment-after-pulmonary-delivery-in-three-different-species
#17
Danielle Freches, Harshad P Patil, Maria Machado Franco, Catherine Uyttenhove, Sam Heywood, Rita Vanbever
The PEGylation of antibody fragments has been shown to greatly prolong their residence time in the lungs in mice. The purpose of this research was to confirm the effect of PEGylation in higher animal species, that is, the rat and the rabbit. An anti-IL-17A Fab' antibody fragment was conjugated to a two-armed 40kDa polyethylene glycol (PEG) via site-selective thiol PEGylation. PEGylation did not significantly alter the binding activity of the Fab' fragment but it largely enhanced its inhibitory potency. PEGylation increased the residence time of the Fab' in the lungs of mice, rats and rabbits...
February 9, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28187379/novel-doxorubicin-loaded-pegylated-cuprous-telluride-nanocrystals-for-combined-photothermal-chemo-cancer-treatment
#18
Xianwen Wang, Yan Ma, Huajian Chen, Xiaoyi Wu, Haisheng Qian, Xianzhu Yang, Zhengbao Zha
Recently, combined photothermal-chemo therapy has attracted great attention due to its enhanced anti-tumor efficiency via synergistic effects. Herein, PEGylated cuprous telluride nanocrystals (PEGylated Cu2Te NCs) were developed as novel drug nanocarriers for combined photothermal-chemo treatment of cancer cells. PEGylated Cu2Te NCs were fabricated through a simple two-step process, comprised of hot injection and thin-film hydration. The as-prepared PEGylated Cu2Te NCs (average diameter of 5.21±1.05nm) showed a noticeable photothermal conversion efficiency of 33...
February 6, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/28186161/genetic-variants-in-interferon-%C3%AE-4-influences-hcv-clearance-in-chinese-han-population
#19
Peng Huang, Yinan Yao, Ming Yue, Ting Tian, Hongbo Chen, Mingzhu Chen, Jie Wang, Yun Zhang, Rongbin Yu
Recent many studies indicated a novel dinucleotide variant in ss469415590 (TT vs. ΔG) of interferon-λ 4 (IFNL4) gene strongly associated with hepatitis C virus clearance. To evaluate the impact and clinical usefulness of IFNL4 ss469415590 genotype on predicting both spontaneous HCV clearance and response to therapy in Chinese population, we genotyped 795 chronic HCV carriers, 460 subjects with HCV natural clearance and 362 patients with pegylated interferon-α and ribavirin (PEG IFN-α/RBV) treatment. IFNL4 ss469415590 variant genotypes significantly decreased host HCV clearance, both spontaneous (dominant model: OR = 0...
February 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28184390/gold-nanoparticle-interactions-with-endothelial-cells-cultured-under-physiological-conditions
#20
C Freese, L Anspach, R C Deller, S-J Richards, M I Gibson, C J Kirkpatrick, R E Unger
PEGylated gold nanoparticles (AuNPs) have an extended circulation time after intravenous injection in vivo and exhibit favorable properties for biosensing, diagnostic imaging, and cancer treatment. No impact of PEGylated AuNPs on the barrier forming properties of endothelial cells (ECs) has been reported, but recent studies demonstrated that unexpected effects on erythrocytes are observed. Almost all studies to date have been with static-cultured ECs. Herein, ECs maintained under physiological cyclic stretch and flow conditions and used to generate a blood-brain barrier model were exposed to 20 nm PEGylated AuNPs...
February 10, 2017: Biomaterials Science
keyword
keyword
41101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"